Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy

Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe ca...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Dario Roccatello, Savino Sciascia, Stefano Murgia, Giacomo Quattrocchio, Michela Ferro, Emanuele De Simone, Carla Naretto, Antonella Barreca, Andrea Sammartino, Daniela Rossi, Roberta Fenoglio
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-03-01
Saila:	Frontiers in Immunology
Gaiak:	ANCA-associated vasculitis rituximab glomerulonephritis vasculitis polyangiitis and granulomatosis polyangiitis
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.777134/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!